You are here

Pfizer Oncology Press Kit

PLEASE NOTE: All assets on this page are intended for use by U.S. media professionals only.

At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference on the lives of patients. Today, Pfizer Oncology has an industry-leading portfolio of 22 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, prostate, kidney and lung cancers, as well as leukemia and melanoma. Pfizer Oncology is striving to change the trajectory of cancer.

For the latest information on our growing pipeline, product portfolio and collaborations with the broader cancer community, visit this page periodically for updates.

Learn more and download an overview of our products pipeline and strategic approach.

Learn more about Pfizer Oncology’s data presentations at European Society for Medical Oncology (ESMO) Congress 2019.

PFIZER ABSTRACT PLAIN LANGUAGE SUMMARIES (APLS) AT ESMO

To help interested non-scientists better understand the latest research, we are developing summaries in plain language for Pfizer research results presented at medical conferences. We call these “abstract plain language summaries” (APLS). To help interested non-scientists better understand the latest research, we are developing summaries in plain language for Pfizer research results presented at medical conferences. We call these “abstract plain language summaries” (APLS).

Body: 

GET TO KNOW PFIZER